Trial
NCT02943473
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Pharmacyclics LLC.
Condition
High Risk Smoldering Multiple Myeloma
Intervention
Ibrutinib
Why stopped
Poor accrual and risk/benefit ratio.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-16